Table 3 Golimumab retention rates after discontinuation of non-TNFi versus after discontinuation of TNFi, by line of therapy
Golimumab after discontinuation of non-TNFi (n = 125) | Golimumab after discontinuation of TNFi (n = 509) | p log-rank | |||
|---|---|---|---|---|---|
n | Retention rate (95% confidence interval) | n | Retention rate (95% confidence interval) | ||
Second line | 26 | 279 | |||
Year 1 | 13 | 62.1 (39.3–78.5) | 185 | 70.5 (64.7–75.5) | 0.119 |
Year 2 | 7 | 38.0 (16.9–59.0) | 139 | 59.1 (52.8–64.7) | |
Year 3 | 5 | 31.6 (12.3–53.1) | 112 | 55.0 (48.7–60.9) | |
Year 4 | 2 | 31.6 (12.3–53.1) | 81 | 48.4 (41.9–54.7) | |
Third line | 29 | 139 | |||
Year 1 | 20 | 69.0 (48.8–82.5) | 80 | 66.1 (57.5–73.4) | 0.838 |
Year 2 | 14 | 56.9 (36.4–73.0) | 65 | 59.0 (49.9–66.9) | |
Year 3 | 7 | 51.7 (31.0–68.9) | 48 | 50.0 (40.7–58.6) | |
Year 4 | 4 | 43.1 (21.0–63.5) | 33 | 44.4 (35.0–53.4) | |
Fourth/subsequent line | 70 | 91 | |||
Year 1 | 34 | 56.2 (43.6–67.1) | 46 | 57.5 (46.5–67.0) | 0.554 |
Year 2 | 18 | 43.0 (29.8–55.4) | 34 | 46.9 (35.9–57.1) | |
Year 3 | 11 | 36.9 (23.6–50.3) | 25 | 43.6 (32.6–54.1) | |
Year 4 | 7 | 28.7 (15.3–43.6) | 16 | 33.5 (22.5–44.9) | |